Modality
Radioligand
MOA
Anti-Aβ
Target
Tau
Pathway
DDR
PBCHuntington'sAtopic Derm
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
→ May 2026
Phase 1Current
NCT04248219
905 pts·Huntington's
2023-08→2026-05·Terminated
905 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-202mo awayPh2 Data· Huntington's
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Termina…
Catalysts
Ph2 Data
2026-05-20 · 2mo away
Huntington's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04248219 | Phase 1/2 | Huntington's | Terminated | 905 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |